| 2020 |
Yao GQ, Zhu M, Walker J, Insogna K. Identification of a 22 bp DNA cis element that plays a critical role in colony stimulating factor 1-dependent transcriptional activation of the SPHK1 gene. Calcif Tiss Int. July 2020;107(1):52-59. |
0 |
0 |
| 2021 |
Athonvarangkul D, Insogna KL. New therapies for hypophosphatemia-related to FGF23 excess. Calcif Tiss Int. January 2021;108(1):143-157. |
0 |
0 |
| 2011 |
Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL. A clinician's guide to x-linked hypophosphatemia. J Bone Miner Res. July 2011;26(7):1381-1388. |
18 |
15 |
| 2021 |
Jan de Beur SM, Miller PD, Weber TJ, Peacock M, Insogna K, Kumar R, Rauch F, Luca D, Cimms T, Roberts MS, San Martin J, Carpenter TO. Burosumab for the treatment of tumor‐induced osteomalacia. J Bone Miner Res. April 2021;36(4):627-635. |
5 |
4 |
| 2022 |
Minisola S, Arnold A, Belaya Z, Brandi ML, Clarke BL, Hannan FM, Hofbauer LC, Insogna KL, Lacroix A, Liberman U, Palermo A, Pepe J, Rizzoli R, Wermers R, Thakker RV. Epidemiology, pathophysiology, and genetics of primary hyperparathyroidism. J Bone Miner Res. November 2022;37(11):2315-2329. |
5 |
1 |
| 2002 |
Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP. High bone density due to a mutation in LDL-receptor–related protein 5. NEJM. May 16, 2002;346(20):1513-1521. |
47 |
47 |